window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 24, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

cardiovascular disease

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Cereno reports positive 12-month CS1 safety data ahead of Phase 2b PAH trial

    Cereno Scientific has reported encouraging 12-month safety and clinical observations [...]

    June 29, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE expands Lokelma access for hyperkalaemia after draft recommendation

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development

    Scribe Therapeutics secures milestone $1.5BN collaboration with Eli Lilly for in vivo CRISPR program

    Scribe Therapeutics has achieved a second success milestone in its [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Cereno Scientific publishes first peer-reviewed data on HDAC inhibitor CS014 showing antithrombotic effects without bleeding risk

    Cereno Scientific has published the first peer-reviewed paper describing its [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Cereno Scientific submits Phase 2b trial protocol for CS1 in pulmonary arterial hypertension to FDA

    Cereno Scientific has submitted the clinical trial protocol for its [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    New Phesi data shows more than 100 diseases being studied with GLP-1 therapies

    Analysis highlights potential for benefits far beyond obesity, signalling a [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Digital & Data,Opinion & Events

    Cellino and Karis Bio join forces to deliver personalized cell therapy in Asia-Pacific

    Cellino and Karis Bio have announced a strategic partnership to [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Biostate AI raises $12M to build the ‘Netflix’ of molecular diagnostics using RNAseq and GenAI

    Biostate AI has raised $12 million in Series A funding [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Ten-year NHS study supports focal therapy for prostate cancer with fewer side effects
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Mission Therapeutics signs US$292M deal for acute kidney injury programme
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Research & Development
  • Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top